NanoInk Imaging Demonstrates SWIR Imaging of Liquid Tumors in Mouse Models

NanoInk Imaging is pleased to announce the successful demonstration of its short-wave infrared (SWIR) imaging technology in mouse models of liquid tumors. In these preliminary studies, NanoInk’s novel contrast agents enabled detection of tumor burden in the bone marrow, a capability not possible with existing imaging technologies without genetic manipulation of tumor cells.

This milestone highlights the unique advantage of NanoInk’s platform: the ability to monitor liquid tumors in vivo without altering their biology. The results represent an important step forward in validating the broad applicability of NanoInk’s technology for both solid and hematologic malignancies, further strengthening the company’s path toward commercialization. Building on these findings, NanoInk is planning expanded preclinical studies and new collaborations to advance the development of its imaging platform.